KPIs & Operating Metrics(New)
Growth Metrics

Bristol Myers Squibb (BMY) Equity Income (2016 - 2024)

Bristol Myers Squibb has reported Equity Income over the past 15 years, most recently at -$23.0 million for Q3 2024.

  • Quarterly Equity Income fell 227.78% to -$23.0 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $12.0 million through Sep 2024, down 84.42% year-over-year, with the annual reading at -$4.0 million for FY2019, 104.3% down from the prior year.
  • Equity Income was -$23.0 million for Q3 2024 at Bristol Myers Squibb, down from $28.0 million in the prior quarter.
  • Over five years, Equity Income peaked at $40.0 million in Q3 2021 and troughed at -$23.0 million in Q3 2024.
  • The 4-year median for Equity Income is $23.0 million (2023), against an average of $13.7 million.
  • The largest YoY upside for Equity Income was 354.55% in 2024 against a maximum downside of 227.78% in 2024.
  • A 4-year view of Equity Income shows it stood at $30.0 million in 2020, then soared by 33.33% to $40.0 million in 2021, then plummeted by 55.0% to $18.0 million in 2023, then plummeted by 227.78% to -$23.0 million in 2024.
  • Per Business Quant, the three most recent readings for BMY's Equity Income are -$23.0 million (Q3 2024), $28.0 million (Q2 2024), and $18.0 million (Q3 2023).